Cannabis Industry Projected to Experience Significant Growth While Legalization Efforts Pick Up Steam - Seite 3

mCig Inc. (OTC: MCIG) announced on Tuesday that its STARTUP Supply Division reached $1.5M in sales during its first year of operations. MCIG's supply division has become the "goto" organization for supplies needed in support of the recreational and medical cannabis movement in Nevada. With a well-developed infrastructure headquartered in Las Vegas, Cannabiz Supply, MCIG's supply division operational entity, recently expanded operations into Southern California and is currently in the planning stages of opening a Colorado operation. The Cannabis market continues to exceed all expectations since in the USA and worldwide. Cannabiz Supply has recently entered into negotiations with two of the largest production empires and anticipates becoming their sole source provider in the upcoming months, further entrenching the operations in this blooming market.

PotNetwork Holding Inc. (OTC: POTN) came to a close up 4.68% on Tuesday with a volume north of 2.6 million. Last week, the company announced over $2 million in sales revenues recorded for the month of April. Compared with the $1,009,900 the company achieved in April of 2017, April 2018's revenues represent a 98% year over year increase. PotNetwork Holdings, Inc.'s wholly owned subsidiary Diamond CBD, Inc. recently revealed that Diamond CBD's Vape Additive, Liquid Gold Vape Juice, Chill Gummies, Tinctures and Biotech Creams, are the brand's most successful products according to the 2018 Investor Relations FAQ, and are being sold in 1000's of retail locations across the United States. According to the PotNetwork Holdings, Inc. 2018 Investor Relations FAQ, Diamond CBD's products are selling best in Texas, California, Florida, Georgia and New York. By virtue of Diamond CBD's success in the 4 most populous states in the country, and with close to 25% of its revenues coming from ecommerce, Diamond CBD emerges as market leader in the U.S. domestic hemp-derived CBD oil market.

INSYS Therapeutics Inc. (NASDAQ: INSY) recently announced that an expert panel convened by the U.S. Food and Drug Administration (FDA) voted not to recommend approval of the company's New Drug Application (NDA) for a buprenorphine sublingual spray as a treatment for moderate-to-severe acute pain. "We appreciate the panelists' perspective and guidance," said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics. "Believing that our sublingual delivery technology could contribute significantly to bring value to patients, we will continue to work with the FDA in the coming months to discuss the path forward for our buprenorphine product candidate and to build on the current body of evidence for its efficacy and safety." INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients' quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products.